Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges.

ZUDDAS, ALESSANDRO;CARUCCI, SARA;
2014

Abstract

In children and adolescents with conduct disorder (CD), pharmacotherapy is considered when non-pharmacological interventions do not improve symptoms and functional impairment. Risperidone, a second-generation antipsychotic is increasingly prescribed off-label in this indication, but its efficacy and tolerability is poorly studied in CD, especially in young people with normal intelligence. The Paediatric European Risperidone Studies (PERS) include a series of trials to assess short-term efficacy, tolerability and maintenance effects of risperidone in children and adolescents with CD and normal intelligence as well as long-term tolerability in a 2-year pharmacovigilance. In addition to its core studies, secondary PERS analyses will examine moderators of drug effects. As PERS is a large-scale academic project involving a collaborative network of expert centres from different countries, it is expected that results will lead to strengthen the evidence base for the use of risperidone in CD and improve standards of care. Challenging issues faced by the PERS consortium are described to facilitate future developments in paediatric neuropsychopharmacology.
Inglese
23
12
1149
1160
12
Esperti anonimi
internazionale
scientifica
Glennon, J; Purper Ouakil, D; Bakker, M; Zuddas, Alessandro; Hoekstra, P; Schulze, U; Castro Fornieles, J; Santosh Paramala, J; Arango, C; Kolch, M; Coghill, D; Flamarique, I; Penzol, Mj; Wan, M; Murray, M; Wong, Ick; Danckaerts, M; Bonnot, O; Falissard, B; Masi, G; Fegert, Jm; Vicari, S; Carucci, Sara; Dittmann, Rw; Buitelaar, J. K.
1.1 Articolo in rivista
info:eu-repo/semantics/article
1 Contributo su Rivista::1.1 Articolo in rivista
262
25
open
Files in This Item:
File Size Format  
ECAP Glennon 013 -PERS.pdf

open access

Type: versione post-print
Size 249.44 kB
Format Adobe PDF
249.44 kB Adobe PDF View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Questionnaire and social

Share on:
Impostazioni cookie